European Society for Medical Oncology (ESMO) shared a post on LinkedIn:
“Antibody – drug conjugates (ADCs) have redefined treatment paradigms across multiple tumor types in a still evolving field.
From proof-of-concept to widespread clinical implementation, ADCs are shaping routine Cancer Care while driving advances in biomarker development, trial design and Precision Medicine. Despite these advances the questions on patient selection, resistance mechanisms, toxicity management and optimal sequencing strategies remain.
Check out the ESMO Daily Reporter for a broad collection of articles on ADCs in oncology.”
Other articles about Precision Medicine on OncoDaily.